Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.
Autonomic
Canagliflozin
Cardiovascular
Dapagliflozin
Diabetes
Empagliflozin
Inhibitors
Neural
SGLT2
Sympathetic
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
accepted:
19
10
2020
pubmed:
11
11
2020
medline:
15
12
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
Recent clinical trials involving the systemic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have revealed beneficial outcomes pertaining to the microvascular sequelae of type 2 diabetes mellitus (T2DM) such as nephropathy, as well as macrovascular effects such as major adverse cardiovascular effects (MACE). Such findings have spurred the elevation of these agents to level A-tiers of recommendation within clinical guidelines addressing the management of complicated T2DM. While the mechanisms of SGLTi (-flozin drugs) are still being elucidated, a paucity of data exists within the literature appraising the role of neuromodulation and associated mechanisms in the aforementioned outcome studies. Given the role of the nervous system in orchestrating the pathologic processes that hamper cardio-renal status, insight into this topic offers an expanded perspective on T2DM. In this review we investigate the mechanisms by which SGLTi improve cardio-renal function in T2DM patients with emphases on neural tone and nervous system physiology.
Identifiants
pubmed: 33169337
doi: 10.1007/s10741-020-10046-w
pii: 10.1007/s10741-020-10046-w
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Canagliflozin
0SAC974Z85
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-652Références
Centers for Disease, C. & Prevention (2017) National chronic kidney disease fact sheet, 2017. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
Afkarian M et al (2016) Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316:602–610
pubmed: 27532915
pmcid: 5444809
Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular diabetology 17:83
pubmed: 29884191
pmcid: 5994068
McCullough PA (2019) Cardiorenal risk: an important clinical intersection. Reviews in cardiovascular medicine 3:71–76
Bailey CJ, Day C (2019) The future of new drugs for diabetes management. Diabetes Res Clin Pract 155:107785
pubmed: 31326453
Ronco C et al (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31:703–711
pubmed: 20037146
Di Lullo L, Bellasi A (2019) Classification of cardiorenal syndrome. In Critical Care Nephrology. Elsevier 670–677
Wang Y et al (2020) Poor renal and cardiovascular outcomes in patients with biopsy-proven diabetic nephropathy. Kidney and Blood Pressure Research 45:378–390
pubmed: 32209792
American Diabetes A (2020) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes care 43:S98–S110
Rieg T, Vallon V (2018) Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61:2079–2086
pubmed: 30132033
pmcid: 6124499
Liu JJ, Lee T, DeFronzo RA (2012) Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes 61:2199–2204
pubmed: 22923645
Novikov A, Vallon V (2016) SGLT2 inhibition in the diabetic kidney–an update. Curr Opin Nephrol Hypertens 25:50
pubmed: 26575393
pmcid: 4703043
Silva-Cardoso J et al (2020) Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials. Journal of diabetes 12:279–293
pubmed: 31688975
Rastogi A, Bhansali A (2017) SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review. Diabetes Therapy 8:1245–1251
pubmed: 29076040
pmcid: 5688986
McMurray JJV et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008
pubmed: 31535829
Petrie MC et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323:1353–1368
pubmed: 32219386
pmcid: 7157181
Shen MJ, Zipes DP (2014) Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 114:1004–1021
pubmed: 24625726
Franciosi S et al (2017) The role of the autonomic nervous system in arrhythmias and sudden cardiac death. Autonomic Neuroscience 205:1–11
pubmed: 28392310
Carbone S, Dixon DL (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular diabetology 18:64
pubmed: 31138195
pmcid: 6540565
Neal B et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England journal of medicine 377:644–657
pubmed: 28605608
Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England journal of medicine 373:2117–2128
pubmed: 26378978
Inzucchi SE et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356–363
pubmed: 29203583
Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114
pubmed: 27289126
Verrotti A, Prezioso G, Scattoni R, Chiarelli F (2014) Autonomic neuropathy in diabetes mellitus. Frontiers in endocrinology 5:205
pubmed: 25520703
pmcid: 4249492
Tawfik EA, Walker FO, Cartwright MS, El-Hilaly RA (2017) Diagnostic ultrasound of the vagus nerve in patients with diabetes. J Neuroimaging 27:589–593
Gourine A, Gourine AV (2014) Neural mechanisms of cardioprotection. Physiology 29:133–140
pubmed: 24583769
pmcid: 3949205
Lewis ME et al (2001) Vagus nerve stimulation decreases left ventricular contractility in vivo in the human and pig heart. The Journal of physiology 534:547–552
pubmed: 11454971
pmcid: 2278718
Kannenkeril D et al (2018) Early vascular parameters in the micro-and macrocirculation in type 2 diabetes. Cardiovascular diabetology 17:128
pubmed: 30231923
pmcid: 6146516
Severino P et al (2019) Myocardial ischemia and diabetes mellitus: role of oxidative stress in the connection between cardiac metabolism and coronary blood flow. Journal of diabetes research 2019
Stuart CA et al (2013) Slow-twitch fiber proportion in skeletal muscle correlates with insulin responsiveness. The journal of clinical endocrinology & metabolism 98:2027–2036
Stefano GB, Challenger S, Kream RM (2016) Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders. Eur J Nutr 55:2339–2345
pubmed: 27084094
pmcid: 5122622
Zuo L, Chuang C-C, Hemmelgarn BT, Best TM (2015) Heart failure with preserved ejection fraction: defining the function of ROS and NO. J Appl Physiol 119:944–951
pubmed: 25977452
Montanez R, Rodriguez-Caso C, Sanchez-Jimenez F, Medina MA (2008) In silico analysis of arginine catabolism as a source of nitric oxide or polyamines in endothelial cells. Amino Acids 34:223–229
pubmed: 17520329
Van Linthout S, Miteva K, Tschöpe C (2014) Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res 102:258–269
pubmed: 24728497
Thomas GD (2011) Neural control of the circulation. Adv Physiol Educ 35:28–32
pubmed: 21385998
Biaggioni I et al (2019) Blood pressure management in afferent baroreflex failure: JACC review topic of the week. J Am Coll Cardiol 74:2939–2947
pubmed: 31806138
pmcid: 6939863
Swenne CA (2013) Baroreflex sensitivity: mechanisms and measurement. Netherlands Heart Journal 21:58–60
pubmed: 23179611
Florea VG, Cohn JN (2014) The autonomic nervous system and heart failure. Circ Res 114:1815–1826
pubmed: 24855204
La Rovere MT, Pinna GD, Maestri R, Sleight P (2013) Clinical value of baroreflex sensitivity. Netherlands Heart Journal 21:61–63
pubmed: 23184601
Cseh D et al (2020) Type 2 diabetes mellitus is independently associated with decreased neural baroreflex sensitivity: the Paris Prospective Study III. Arterioscler Thromb Vasc Biol 40:1420–1428
pubmed: 32188272
Okada N et al (2010) Baroreflex sensitivity predicts cardiovascular events in patients with type 2 diabetes mellitus without structural heart disease. Circ J 74:1379–1383
pubmed: 20453396
Hermann GE, Rogers RC (2008) TNF α: a trigger of autonomic dysfunction. The Neuroscientist 14:53–67
pubmed: 17911224
Hamaoka T et al (2019) 1417 Effect of sodium glucose cotransporter 2 inhibitor on sympathetic nerve activity in type 2 diabetes mellitus patients. Eur Heart J 40:ehz748-0064
Sato T et al (2017) Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with type 2 diabetes. Diabet Med 34:1367–1371
pubmed: 28703863
Malik M, Batchvarov VN (2000) Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 36:1749–1766
pubmed: 11092641
Verma S et al (2019) Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care 42:e42–e44
pubmed: 30674547
Ninkovic VM et al (2016) Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol 53:737–744
pubmed: 27107571
pmcid: 5014905
Fisher VL, Tahrani AA (2017) Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes, metabolic syndrome and obesity: targets and therapy 10:419
Wiviott SD et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England journal of medicine 380:347–357
pubmed: 30415602
Kiuchi S et al (2018) Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. Drug discoveries & therapeutics 2017–01069
Manti S, Brown P, Perez MK, Piedimonte G (2017) The role of neurotrophins in inflammation and allergy. In Vitamins and hormones 104:313-341. Elsevier
Eyileten C, Kaplon-Cieslicka A, Mirowska-Guzel D, Malek L, Postula M (2017) Antidiabetic effect of brain-derived neurotrophic factor and its association with inflammation in type 2 diabetes mellitus. Journal of diabetes research 2017
Li B, Lang N, Cheng Z-F (2016) Serum levels of brain-derived neurotrophic factor are associated with diabetes risk, complications, and obesity: a cohort study from Chinese patients with type 2 diabetes. Mol Neurobiol 53:5492–5499
pubmed: 26454822
Morel L, Domingues O, Zimmer J, Michel T (2020) Revisiting the role of neurotrophic factors in inflammation. Cells 9:865
pmcid: 7226825
Motamedi S, Karimi I, Jafari F (2017) The interrelationship of metabolic syndrome and neurodegenerative diseases with focus on brain-derived neurotrophic factor (BDNF): kill two birds with one stone. Metab Brain Dis 32:651–665
pubmed: 28361262
Lee P-G, Hohman TC, Cai F, Regalia J, Helke CJ (2001) Streptozotocin-induced diabetes causes metabolic changes and alterations in neurotrophin content and retrograde transport in the cervical vagus nerve. Exp Neurol 170:149–161
pubmed: 11421592
Araya AV, Orellana X, Espinoza J (2008) Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences. Endocrine 33:300–304
pubmed: 19012000
Tahrani AA, Barnett AH, Bailey CJ (2013) SGLT inhibitors in management of diabetes. The lancet Diabetes and endocrinology 1:140–151
pubmed: 24622320
Thewjitcharoen Y et al (2017) Effectiveness of long-term treatment with SGLT2 inhibitors real-world evidence from a specialized diabetes center. Diabetology and metabolic syndrome 9:96
pubmed: 29213337
Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5(1):133–141
pubmed: 19965550
Chaldakov GN et al Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brainderived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50: 431–438. Diabetologia 50:1781-1782.
Krabbe KS et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431–438
pubmed: 17151862
Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A (2020) Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci 240:117090
pubmed: 31765648
Ali A et al (2019) SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice. Diabetes Therapy, 1–28
Jardine MJ et al (2017) The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46:462–472
pubmed: 29253846
pmcid: 5804835
Perkovic V et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306
pubmed: 30990260
Herat LY et al (2020) SGLT2 inhibitor–induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic to Translational Science 5:169–179
pubmed: 32140623
pmcid: 7046513
Horita S et al (2011) Insulin resistance, obesity, hypertension, and renal sodium transport. International journal of hypertension 2011
Sata Y, Head GA, Denton K, May CN, Schlaich MP (2018) Role of the sympathetic nervous system and its modulation in renal hypertension. Frontiers in Medicine 5:82
pubmed: 29651418
pmcid: 5884873
Kopp UC, Cicha MZ, Yorek MA (2008) Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: role of angiotensin. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 294:R858–R866
pubmed: 18199587
Witzel I-I et al (2015) Identifying common genetic risk factors of diabetic neuropathies. Frontiers in endocrinology 6:88
pubmed: 26074879
pmcid: 4447004
Noh MR, Jang H-S, Kim J, Padanilam BJ (2020) Renal sympathetic nerve-derived signaling in acute and chronic kidney diseases. Int J Mol Sci 21:1647
pmcid: 7084190
Whelan RS, Konstantinidis K, Xiao RP, Kitsis RN (2013) Cardiomyocyte life-death decisions in response to chronic β-adrenergic signaling. Am Heart Assoc
Lovshin JA, Gilbert RE (2015) Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr Hypertens Rep 17:40
von Lueder TG, Kotecha D, Atar D, Hopper I (2017) Neurohormonal blockade in heart failure. Cardiac failure review 3:19
Sekaran NK, Crowley AL, de Souza FR, Resende ES, Rao SV (2017) The role for cardiovascular remodeling in cardiovascular outcomes. Current atherosclerosis reports 19:23
pubmed: 28357714
da Silva ALP, da Silva MJV (2016) Type 4 cardiorenal syndrome. Revista Portuguesa de Cardiologia (English Edition) 35:601–616
Daenen K et al (2019) Oxidative stress in chronic kidney disease. Pediatric Nephrology 34:975–991
pubmed: 30105414
Sutariya B, Jhonsa D, Saraf MN (2016) TGF-β: the connecting link between nephropathy and fibrosis. Immunopharmacol Immunotoxicol 38:39–49
pubmed: 26849902
Sun YBY, Qu X, Caruana G, Li J (2016) The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. Differentiation 92:102–107
pubmed: 27262400
Liu G, Ma C, Yang H, Zhang P-Y (2017) Transforming growth factor β and its role in heart disease. Experimental and therapeutic medicine 13:2123–2128
pubmed: 28565818
pmcid: 5443237
Segura AM, Frazier OH, Buja LM (2014) Fibrosis and heart failure. Heart Fail Rev 19:173–185
pubmed: 23124941
Shokoji T et al (2004) Effects of local administrations of tempol and diethyldithio-carbamic on peripheral nerve activity. Hypertension 44:236–243
pubmed: 15262907
Xu H, Fink GD, Galligan JJ (2004) Tempol lowers blood pressure and sympathetic nerve activity but not vascular O2− in DOCA-salt rats. Hypertension 43:329–334
pubmed: 14707156
Ahmeda AF, Rae MG, Johns EJ (2013) Effect of reactive oxygen species and nitric oxide in the neural control of intrarenal haemodynamics in anaesthetized normotensive rats. Acta Physiol 209:156–166
Osorio H et al (2012) Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract 97:276–282
pubmed: 22429686
Yamauchi K (2018) Sglt2 inhibitors suppress alpha-adrenergic tone and morning elevation of plasma glucose levels. Am Diabetes Assoc